Altamira Therapeutics regains compliance with Nasdaq minimum equity requirement

Altamira Therapeutics announced that it recently received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, informing the company that it has regained compliance with the minimum stockholders’ equity requirement as set forth under Nasdaq Listing Rule 5550(b)(1) for continued listing on Nasdaq. The company had boosted its equity position through a public offering of common shares in July, the partial amortization of convertible debt granted by FiveT Investment Management as well as, most recently, the partial spin-off of its Bentrio activities. Nasdaq will continue to monitor the company’s ongoing compliance with the stockholders’ equity requirement.